Halozyme Therapeutics (HALO) is a biopharmaceutical company "bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies". We last covered HALO on March 4, 2021 where we wrote that, "I will assume that traders took profits on HALO on strength in the $48 to $55 area. HALO now looks like it can correct to the $34 to $30 area in the weeks ahead. Stand aside."
Let's check out the charts again as HALO is my "top pick" for the second quarter.